Replies to post #327849 on Innovation Pharmaceuticals Inc (IPIX)

[loanranger]

Thanks for responding.
I was asking "for what?" in response to the assertion that we were "Waiting for RBL" and you're right to point out that "The RBL ought to be finishing the data for prepublication." From an investor relations and a third party scientific verification standpoint that pre-print is important.
But what I really wanted to know was how the RBL plays into the timing of the IND application. I could be mistaken but I don't recall the subjects of pre-prints and peer review coming up as contingencies prior to any of the handful of INDs that the Company has submitted in the past.

We aren't "waiting for RBL" in order to submit the B-CoVid IND, are we? Hasn't the data required to submit the IND been in hand for some time? My understanding was that the $35k bought what was needed and that it was provided as planned in late August:
http://www.ipharminc.com/press-release/2020/8/24/covid-19-drug-candidate-brilacidin-achieves-a-selectivity-index-among-the-highest-reported-exhibiting-potent-anti-sars-cov-2-activity-at-low-concentrations-clinical-trial-forthcoming

Does the FDA need something that the RBL has yet to provide in order to review an IND application or, if not, what information might still be needed in order to apply?